Jump to content
RemedySpot.com

Revised guidelines for the Prevention of OI

Rate this topic


Guest guest

Recommended Posts

Guest guest

July 2001 DRAFT: 2001 USPHS/IDSA Guidelines for the Prevention of

Opportunistic Infections in Persons Infected with Human

Immunodeficiency Virus

ATIS Guidelines page

http://hivatis.org/trtgdlns.html

Direct link to PDF of document

http://www.hivatis.org/guidelines/OIGuidelinesJuly2001.pdf

" Major changes in the guidelines since 1999 include:

Higher level ratings have been provided for discontinuing primary

prophylaxis for PCP and MAC when CD4+ T lymphocytes have increased to

>200 cells/µL and >100 cells/µL, respectively, for 3 months in

response to HAART (AI), and a new recommendation to discontinue

primary toxoplasma prophylaxis has been provided when the CD4+ T

lymphocyte count has increased to >200 cells/µL for 3 months (AI).

· Secondary PCP prophylaxis should be discontinued in patients whose

CD4+ counts have increased to >200 cells/µL for 3 months as a

consequence of HAART (BII).

· Secondary prophylaxis for disseminated MAC may be discontinued in

patients with a sustained (e.g., 6 months) increase in CD4+ count to

>100cells/µL in response to HAART if they have completed 12 months of

MAC therapy and have no symptoms or signs attributable to MAC (CIII).

· Secondary prophylaxis for toxoplasmosis and cryptococcosis may be

discontinued in patients with a sustained increase in CD4+ counts

(e.g. >6 months) to >200 cells/µL and greater than >100-200cells/µL

respectively, in response to HAART if they have completed their

initial therapy and have no symptoms or signs attributable to these

pathogens (CIII).

· The importance of screening all HIV-infected individuals for

hepatitis C virus (HCV) is emphasized(BIII).

· Additional information about transmission of human herpesvirus 8

infection (HHV-8) is provided.

· New information on drug interactions is provided, especially with

regard to rifamycins and antiretroviral drugs.

· Revised recommendations for immunization of HIV exposed/infected

adults and children are provided. "

_______________________

Comments should be directed to : Henry Masur MD, Clinical Center 7D43,

National Institutes of Health, Bethesda, MD 20892 or to

hmasur@... until September 1, 2001.

______________________________

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...